Back to results
US 11,896,648 B2Granted
Interleukin-2 variant proteins fused to human IgG4 Fc and uses thereof
AssigneeGilead Sciences, Inc.
InventorsManuel Baca, Sarah A. Gilmore, Hassan Javanbakht, Prasenjit K. Mukherjee
Life of this patent
Estimating the term…
Abstract
Provided are serum half-life extended-IL-2 variant (IL-2v) heterodimers having reduced binding to the IL2Rα (CD25) subunit. In particular, Fc-IL-2v heterodimers are provided and methods for making and using, e.g. for enhancing an immune response, e.g. in the prevention and treatment of viral infections and cancer.
Claims14
A heterodimer comprising a human IgG4 Fc-IL-2v fusion protein comprising (i) a first amino acid sequence of SEQ ID NO:
- 114 comprising a first Fc domain;
- and (ii) a second Fc domain comprising an amino acid sequence of SEQ ID NO:
- 46.
Dependencies are inferred from the claim text.